Company Encyclopedia
View More
name
Aethlon Medical
AEMD.US
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
1.407 T
AEMD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

    Aethlon Medical Inc. announced preclinical data showing its Hemopurifier® device binds to extracellular vesicles in Long COVID patients, reducing inflammatory microRNAs. Published on bioRxiv, the study suggests the device removes elevated EVs in these patients. NanoString analyses identified seven microRNAs significantly reduced by the treatment. The findings support further investigation but are not yet in clinical trials. The news was generated by AI and is for informational purposes only.

    Reuters·
    US
    AEMD
    +8.92%
    Reuters·
    US
    AEMD
    +8.92%

    Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)

    Maxim Group's Anthony Vendetti reaffirmed a Hold rating on Aethlon Medical (AEMD) in a report dated November 12. The stock closed at $4.20. Vendetti, with an average return of -23.2% and a 25.86% success rate, covers the Healthcare sector. The analyst consensus for Aethlon Medical remains a Hold rating.

    Tip Ranks·
    US
    AEMD
    +8.92%
    Tip Ranks·
    US
    AEMD
    +8.92%

    Aethlon Medical’s Earnings Call: Progress Amid Challenges

    Aethlon Medical's Q2 earnings call highlighted progress in clinical trials and a 48% reduction in operating expenses. Challenges include slow patient recruitment for oncology trials and concerns over cash reserves. The Australian oncology trial showed promising results, advancing to Cohort 2. Financially, Aethlon reported a cash balance of $5.8 million, raising sustainability concerns. The company is focusing on core projects and resource optimization to overcome hurdles.

    Tip Ranks·
    US
    AEMD
    +8.92%
    Tip Ranks·
    US
    AEMD
    +8.92%

    Aethlon Medical shares are trading higher. The company reported Q2 financial results.

    benzinga_article·
    US
    AEMD
    +8.92%
    benzinga_article·
    US
    AEMD
    +8.92%

    Aethlon Medical | 10-Q: FY2026 Q2 Revenue: USD 0

    LB filings·
    US
    AEMD
    +8.92%
    LB filings·
    US
    AEMD
    +8.92%
    © 2025 Longbridge｜Disclaimer